• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline
provides recommendations and algorithms for clinicians to diagnose and manage …

In view of the increasing complexity of both cardiovascular implantable electronic devices
(CIEDs) and patients in the current era, practice guidelines, by necessity, have become …

Sudden cardiac death (SCD) is an unexpected sudden death due to a heart condition, that
occurs within one hour of symptoms onset. SCD is a leading cause of death in western …

Hypertrophic cardiomyopathy (HCM), a relatively common, globally distributed, and often
inherited primary cardiac disease, has now transformed into a contemporary highly treatable …

Aims Childhood-onset hypertrophic cardiomyopathy (HCM) is far less common than adult-
onset disease, thus natural history is not well characterized. We aim to describe the …

Purpose Genetic testing has advanced significantly since the publication of the 2011
HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the …

RASopathies are a group of developmental multisystemic disorders caused by germline
mutations in genes encoding signal transducers and regulatory proteins functionally linked …